2 Min Read
FILE PHOTO: The logo of the Carlyle Group is displayed at the company s office in Tokyo, Japan October 17, 2018. REUTERS/Issei Kato
HONG KONG (Reuters) - Chinese biotech company Abbisko Therapeutics Co has raised $123 million from more than a dozen investors, including Carlyle Group and Warburg Pincus, in its latest funding round, the company said on Friday.
Abbisko said in a news release that Carlyle led the latest fundraising with Warburg, OrbiMed, Lake Bleu Capital, and an unnamed Boston-based investor as the joint leading investors.
Other investors include Janchor Partners, Sage Partners, SHC and Greater Bay Area Homeland Development Fund.
Hong Kong: I&T fund adds new partners
The Innovation & Technology Commission today announced that the Innovation & Technology Venture Fund has added three venture capital funds as co-investment partners.
The commission called for a new round of applications from venture capital funds to become co-investment partners of the fund early this year.
It received 11 applications.
Based on the assessment criteria including the venture capital fund s capability, its investment strategy and performance, its management team s expertise and experience and its local network and resources, as well as the advice of the fund’s advisory committee, the commission selected three co-investment partners at the first stage.